Checkpoint Inhibitors in Cancer Care
Jeffrey A. Sosman, MD, from the Vanderbilt University School of Medicine and Vanderbilt-Ingram Cancer Center, discusses the use of checkpoint inhibitors in cancer care.
Immune Response in Patients with RCC
Jeffrey A. Sosman, MD, professor of medicine, director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses immune response in renal cell carcinoma.
Immunotherapy Treatment for Melanoma and Renal Cancer
Jeffrey A. Sosman, MD, discusses how immunotherapies work in patients with melanoma or renal cancer.
Ipilimumab 3 mg/kg vs 10 mg/kg in Metastatic Melanoma
Jeffrey A. Sosman, MD, from the Vanderbilt-Ingram Cancer Center, discusses a trial comparing two doses of ipilimumab for patients with metastatic melanoma.
Drug Sequencing in Melanoma
Jeffrey A. Sosman, MD, from the Vanderbilt-Ingram Cancer Center, discusses drug sequencing for patients with melanoma at the 11th Annual International Congress on Targeted Therapies in Cancer.